



	<b>Program Schedule</b>
<b>November 13</b>	
7:45 – 8:15	<b>Registration</b>
8:15 – 8:30	<b>Welcome and Program Overview/Pre-Test</b> – <i>Stacey Rizza, M.D., John Wilson, M.D. &amp; Zelalem Temesgen, M.D.</i>
8:30 – 8:45	<b>Epidemiology of Tuberculosis</b> – <i>Dzung Thai, M.P.H</i> <ul style="list-style-type: none"><li>• Describe the TB epidemic in terms of susceptible groups</li><li>• Describe major factors that will affect future trends in TB</li></ul>
8:45 – 9:30	<b>TB Pathogenesis</b> – <i>Stacey Rizza, M.D.</i> <ul style="list-style-type: none"><li>• Describe the pathogenesis of <i>M. tuberculosis</i></li></ul>
9:30 – 10:15	<b>TB Transmission &amp; Infection Control</b> – <i>E. Ann Misch, M.D.</i> <ul style="list-style-type: none"><li>• Explain how drug-resistant TB disease develops</li><li>• Describe the components of an effective infection control program</li><li>• Explain administrative, engineering controls, and respiratory protection</li></ul>
10:15 – 10:30	<b>Break</b>
10:30 – 11:15	<b>Targeting Testing and Diagnosis of LTBI Infection</b> – <i>Jeremy Clain, M.D.</i> <ul style="list-style-type: none"><li>• Explain Use of TST</li><li>• Explain use of IGRA testing</li></ul>
11:15 – 12:00	<b>Treatment Options for LTBI</b> – <i>Jeremy Clain, M.D.</i> <ul style="list-style-type: none"><li>• Describe treatment options for LTBI</li><li>• Review monitoring strategies for TB patients with co-morbid conditions</li><li>• Describe monitoring recommendations for patients on LTBI treatment</li></ul>
12:00 – 1:15	<b>Lunch</b>
1:15 – 2:00	<b>Laboratory TB Diagnostics</b> – <i>Nancy Wengenack, Ph.D.</i> <ul style="list-style-type: none"><li>• Describe laboratory methods used for the detection, identification, genotyping, and drug susceptibility testing of <i>M. tuberculosis</i></li></ul>
2:00-3:00	<b>Radiology</b> – <i>Dana Kissner, M.D.</i> <ul style="list-style-type: none"><li>• Identify the major structures on a normal chest x-ray</li><li>• Identify major chest x-ray abnormalities commonly seen in TB</li></ul>
3:00-3:15	<b>Break</b>
3:15-4:00	<b>Interesting Cases</b> – <i>Douglas Hornick, M.D.</i> <ul style="list-style-type: none"><li>• Indicate transfer of knowledge of tuberculosis testing, diagnosis, and treatment to a clinical case.</li></ul>
4:00-4:15	<b>Q&amp;A/Post Test</b>
4:15	<b>Adjourn</b>

## Program Schedule

<b>November 14</b>	
7:45-8:00	<b>Sign in</b>
8:00 – 8:15	<b>Review / Q&amp;A</b>
8:15-9:00	<b>Treatment of TB</b> – <i>James Sunstrum, M.D.</i> <ul style="list-style-type: none"> <li>• Identify the basic principles of drug resistant TB</li> <li>• Describe the current guidelines for the treatment of TB disease including the newly released CDC guidelines</li> </ul>
9:00 – 10:00	<b>TB Drug Toxicity</b> – <i>John Zeuli, Pharm. D.</i> <ul style="list-style-type: none"> <li>• Describe the common adverse reactions to TB treatment regimens</li> <li>• Explain how to manage adverse reactions to TB treatment regimens</li> </ul>
10:00 – 10:15	<b>Break</b>
10:15 - 10:45	<b>TB and Drug Resistance</b> – <i>Dean Tsukayama, M.D.</i> <ul style="list-style-type: none"> <li>• Describe factors responsible for delayed response and/or treatment failure</li> <li>• Describe treatment and management strategies for multidrug-resistant TB</li> </ul>
10:45 – 11:15	<b>TB and Biologics</b> – <i>Claudia Dobler, M.D., Ph.D.</i> <ul style="list-style-type: none"> <li>• Describe concept of immunomodulatory drugs (IMiDs) and development of biologics</li> <li>• Review TNF inhibitors</li> <li>• Identify screening recommendations and controversies</li> </ul>
11:15-11:45	<b>Interesting TB Cases</b> – <i>John Wilson, M.D.</i> <ul style="list-style-type: none"> <li>• Indicate transfer of knowledge of tuberculosis testing, diagnosis, and treatment to a clinical case.</li> </ul>
11:45-1:00	<b>Lunch</b>
1:00-2:00	<b>TB and Diabetes</b> – <i>Richard Brostrom, M.D.</i> <ul style="list-style-type: none"> <li>• Describe the epidemiology of diabetes in the US</li> <li>• Describe the impact of TB on diabetes</li> </ul>
2:00-3:00	<b>Mental Health Considerations</b> – <i>Robert Morgan, III, M.D., Ph.D.</i> <ul style="list-style-type: none"> <li>• Describe historical parallels between tuberculosis and mental illness</li> <li>• Identify drug-drug interactions of concern when prescribing medications to treat tuberculosis to patients with mental illness</li> <li>• Identify and manage challenges arising from comorbid mental illness/substance use disorders that patients may face when confronting tuberculosis treatment</li> </ul>
2:45-3:00	<b>Break</b>
3:00-3:45	<b>Case Presentation</b> – <i>James Sunstrum, M.D.</i> <ul style="list-style-type: none"> <li>• Indicate transfer of knowledge of tuberculosis testing, diagnosis, and treatment to a clinical case.</li> </ul>
3:45-4:00	<b>Resource Review</b> – Jennifer Curran
4:00-4:15	<b>Final Q&amp;A/ Post Test</b> – <i>Stacey Rizza, M.D.</i>